Norway, July 31 -- Thor Medical, a leading supplier of high-purity isotopes to the radiopharmaceutical industry, today announced that its industrial-scale AlphaOne production facility at Herøya Industrial Park has commenced commercial production.The AlphaOne facility will produce lead-212 (Pb-212), and its precursors thorium-228 (Th-228) and radium-224 (Ra-224), supporting the fastest-growing segment of radiotherapeutics, a market projected to reach USD 15 billion by 2030 and USD 28 billion by 2034.Thor Medical has signed supply agreements with numerous customers across the radiopharmaceutical value chain, ranging from early-stage biotech companies to leading CDMOs and global pharmaceutical companies. The company expects to make its first c...